-

Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020

-- Conference Call and Webcast to Follow --

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2020 financial results will be released on Wednesday, October 28, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s third quarter 2020 financial results and will provide a business update.

The live webcast of the call can be accessed at the company’s Investors page at investors.gilead.com. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6986657 to access the call. Telephone replay will be available approximately two hours after the call through 11:59 p.m. Eastern Time, October 30, 2020. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 6986657. The webcast will be archived on www.gilead.com for one year.

About Gilead

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Douglas Maffei, Ph.D.
Investor Relations
(650) 574-3000

Gilead Sciences, Inc.

NASDAQ:GILD

Release Versions

Contacts

Douglas Maffei, Ph.D.
Investor Relations
(650) 574-3000

More News From Gilead Sciences, Inc.

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union. Analyses fr...

Gilead Sciences Announces First Quarter Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Building on the strongest pipel...

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 12 at 2:20 PM Pacific Time RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 11:00 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 28 at 11:00 AM Eastern Time Goldman Sachs Annual Global Healthcare Conference on Tuesday, Ju...
Back to Newsroom